Mayo Clinic researchers studied the outcomes of treating high-risk patients for COVID-19 with a five-day oral regimen of nirmatrelvir and ritonavir, which are together marketed as Paxlovid. Out of 483 high-risk patients, only a handful developed COVID rebound symptoms, and the scientists say more research is needed to determine why.

Mayo Clinic Reveals Data on Rebound COVID-19 Symptoms After Paxlovid Treatment

Overall, the Paxlovid treatment benefited everyone in the study. All patients recovered, including those who developed rebound symptoms, which were generally mild. The findings were published on June 14, 2022, in the journal Mayo Clinic Infectious Diseases. We found that rebound phenomenon was uncommon in this group of patients,” says senior author Aditya Shah, M.B.B.S., a Mayo Clinic infectious diseases physician and researcher. “The four individuals who experienced rebound (symptoms) represent only 0.8% of the group, and all of them recovered quickly without additional COVID-directed therapy.”

Most of the patients in the study had been vaccinated, and many had received booster vaccinations. The median age was 63. While these patients were high-risk for COVID-19, none was immunocompromised. Only two patients were admitted to the hospital, and it was for reasons other than COVID. Researchers think one explanation could be that a replication of the SARS-CoV-2 virus he virus that causes COVID-19 ay have triggered a secondary immune response that showed up as mild COVID-19 symptoms. They suggest further prospective studies could answer the question. They also note that all four patients with rebound symptoms had many serious health problems known as comorbidities a factor known to complicate recoveries. Also, all four patients had been vaccinated more than 90 days before becoming infected with COVID-19.

Source: This news is originally published by scitechdaily

By Web Team

Technology Times Web team handles all matters relevant to website posting and management.